Human papillomavirus (HPV) vaccines: a Canadian update

Area of Science:

• Oncology
• Immunology
• Public Health

Background:

• Human papillomavirus (HPV) is a common sexually transmitted infection linked to cervical, anogenital, and head and neck cancers, as well as genital warts.
• HPV types 16 and 18 are most frequently associated with cervical cancer development.

Purpose of the Study:

• To review the efficacy and safety of available HPV vaccines for primary prevention.
• To identify and discuss unresolved questions and challenges related to HPV vaccination programs.

Main Methods:

• Review of randomized controlled trials on HPV vaccine efficacy and safety.
• Discussion of current status of HPV vaccines (Gardasil, Cervarix) in Canada.
• Identification of key areas requiring further research and policy consideration.

Main Results:

• Two HPV vaccines targeting types 16 and 18 have been studied for efficacy and safety.
• Gardasil is approved in Canada; Cervarix is under review.
• Numerous questions persist regarding optimal vaccination age, duration, target populations (males, already infected), and program implementation.

Conclusions:

• HPV vaccination is a critical tool for primary prevention of HPV-related cancers.
• Addressing remaining questions is essential for maximizing vaccine impact and ensuring equitable access.
• Further research and policy development are needed for comprehensive HPV immunization strategies.